The Thesis
RSI Snap-Back bets on a well-documented behavioural quirk: large-cap technology names — the Magnificent 7 (AAPL, MSFT, NVDA, GOOGL, AMZN, META, TSLA) — tend to recover sharply after short-term panic selling. The strategy enters any name whose 14-day RSI drops below 35, signalling oversold conditions, and exits when RSI climbs above 70, signalling the reversion has largely played out. A hard limit of four concurrent positions enforces capital discipline and prevents the portfolio from becoming a concentrated bet on a single drawdown event.
The logic is sound in principle. These are the most liquid, analyst-covered equities in the world; structural buyers (index funds, buyback programs, institutional accumulation on dips) provide a reliable tailwind that makes prolonged RSI troughs historically short-lived.
Backtest Performance
Over a 451-day backtest period the strategy completed 37 trades, finishing with $12,095 in equity on a $10,000 starting book — a 20.95% total return and an annualised CAGR of 11.21%.
| Metric | Value |
|---|---|
| Total Return | 20.95% |
| CAGR | 11.21% |
| Sharpe Ratio | 0.61 |
| Max Drawdown | 23.73% |
| Win Rate | 66.67% |
| Trades | 37 |
| Turnover | 773% |
A two-thirds win rate is genuinely respectable for a discretionary-style mean-reversion approach. The strategy is not firing blindly — when it does enter, it exits profitably the majority of the time.
The weaker numbers are the Sharpe ratio (0.61) and the maximum drawdown (23.73%). A Sharpe under 1.0 means the strategy's volatility is eating a meaningful share of its returns. A nearly 24% peak-to-trough drawdown on a $10k book is an uncomfortable ride — and in live trading, drawdown pressure is what causes discretionary overrides and premature exits that destroy edge.
Turnover at 773% annually is high. At $1 flat fee per trade the total cost here was $37, which is negligible, but in a real-money account with market-impact costs that figure deserves monitoring as AUM grows.
Recent Activity: Six Quiet Sessions
The last six scheduled runs (June 29 – July 6) all report zero executions and a flat $10,000 cash position. No positions have been opened or closed.
This is not a malfunction — it is the strategy doing exactly what it should do when no name in its universe crosses the RSI < 35 entry threshold. After a sustained rally in large-cap tech through mid-2026, RSI readings across the Mag-7 have largely remained in neutral-to-overbought territory. There is simply no signal.
The practical implication is that the strategy's returns are inherently episodic. Long stretches of inactivity are the cost of waiting for genuine oversold conditions rather than forcing trades.
Risks to Watch
Regime sensitivity. Mean-reversion thrives in range-bound or volatile markets and struggles in strong trending ones. If large-cap tech enters a sustained multi-month uptrend with shallow pullbacks, RSI < 35 may trigger only during genuine breakdowns rather than temporary dips — changing the character of entries entirely.
No walk-forward validation. The validation field is currently null. Backtest returns without an out-of-sample or walk-forward confirmation carry overfitting risk, especially with only 37 trades — too small a sample to be statistically robust on its own.
Concentration. Four names from a seven-stock universe means a sector-wide shock (regulatory action, a broad tech selloff) can hit all open positions simultaneously, which partly explains the 23.73% drawdown figure.
Bottom Line
RSI Snap-Back is a coherent, disciplined strategy with a solid live-trading record in its backtest window. The current idle streak is patience, not failure. The priority before scaling capital should be adding walk-forward validation and stress-testing the drawdown profile against 2022-style sector corrections.